Abstract
Background
We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in this study.
Method
Retrospective data analysis was done on patient treatment records from 1988 to 2018. The patient’s demographic, clinical, pathological, and therapeutic characteristics were noted. To evaluate survival analysis and predictors of recurrence, we employed Kaplan–Meier analysis with the log-rank test.
Results
A total of 357 patients in all were enrolled in the research. At the time of diagnosis, the median age was 50 (with a range of 18–81). A total of 85.5% of patients had undergone a lumpectomy, while 14.5% had a mastectomy. 78.7% of patients had sentinel lymph node biopsy, and 21.3% had axillary lymph node dissection. In addition, the patients received adjuvant radiotherapy (88.7%), adjuvant endocrine therapy (82.1%), and adjuvant chemotherapy (48.5%). Recurrence of the tumor occurred in 31 (8.7%) patients (local recurrence 45.2% and metastatic disease 54.8%). Ten- and twenty-year recurrence-free survival rates were 92% and 77%. 19 (5.3%) patients had also developed contralateral breast cancer. Ten-year survival rates were 91.6%, and 20-year survival rates were 76.6%, respectively. Aged over 65 years (p = 0.004), necrosis (p = 0.002), mitosis (p = 0.003), and nuclear pleomorphism (p = 0.049) were found as statistically significant factors for recurrence in univariate analysis. In the ROC analysis, the largest size of the tumor (over 1.45 cm, p = 0.07) remained outside the statistical significance limit in terms of recurrence.
Conclusions
Thirty-year outcomes in individuals with early stage, node-negative breast cancer were shown in this study. We found that the recurrence ratios between 10 and 20 years were more frequent than the first 10 years during the follow-up. Despite the small number of patients who experienced a recurrence, we demonstrated that, in univariate analysis, being older than 65 and having some pathological characteristics (nuclear pleomorphism, mitosis, and necrosis) were statistically significant factors for disease recurrence.
Similar content being viewed by others
Data availability statement
This published paper contains all of the data produced or analyzed during this investigation. Further enquiries can be directed to the corresponding author.
References
Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885–3891
Billena C, Wilgucki M, Flynn J, Modlin L, Tadros A, Razavi P, Braunstein LZ, Gillespie E, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell S, Khan AJ (2021) 10-year breast cancer outcomes in women </=35 years of age. Int J Radiat Oncol Biol Phys 109(4):1007–1018
Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, Wong JS, Punglia RS, MacDonald SM, Harris JR (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161(1):173–179
Eaker S, Dickman PW, Bergkvist L, Holmberg L, Uppsala G, Cancer OB (2006) Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 3(3):e25
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P (2013) Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 139(5):853–860
Gandhi H, Maru A, Shah N, Mansuriya RK, Rathod G, Parmar P (2023) Correlation of Robinson’s cytological grading with Elston and Ellis’ Nottingham modification of bloom Richardson score of histopathology for breast carcinoma. Maedica (bucur) 18(1):55–60
Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC (2019) Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 5(10):1473–1478
Giannakeas V, Lim DW, Narod SA (2021) The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 125(4):601–610
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (basel) 13(17):4287
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, Ebctcg. (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846
Pedersen RN, Esen BO, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash TL, Norgaard M, Cronin-Fenton D (2022) The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst 114(3):391–399
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26(19):3153–3158
Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM (2010) Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899–2908
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48
Soliman H, Shah V, Srkalovic G, Mahtani R, Levine E, Mavromatis B, Srinivasiah J, Kassar M, Gabordi R, Qamar R, Untch S, Kling HM, Treece T, Audeh W (2020) MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial. BMC Cancer 20(1):81
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Syed YY (2020) Oncotype DX breast recurrence score((R)): a review of its use in early-stage breast cancer. Mol Diagn Ther 24(5):621–632
van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307(6):590–597
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32(20):2142–2150
Zemni I, Ghalleb M, Jbir I, Slimane M, Ben Hassouna J, Ben Dhieb T, Bouzaiene H, Rahal K (2017) Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients. World J Surg Oncol 15(1):206
Funding
Neither financial nor of other nature.
Author information
Authors and Affiliations
Contributions
Conception and design: Dr. ID and Professor Dr. AA; Development of methodology, analysis, and interpretation of data: Dr. ID; Data acquisition: All authors; Manuscript writing: All authors; Final approval of manuscript: All authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declared that there are no potential conflicts of interest.
Ethical approval
The academic board approved this study at the Istanbul University Institute of Oncology (Number: 1723150).
Informed consent
For this type of research, informed consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dogan, I., Aydin, E., Khanmammadov, N. et al. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients. J Cancer Res Clin Oncol 149, 14833–14841 (2023). https://doi.org/10.1007/s00432-023-05276-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05276-y